Shots:

• Obsidian to receive $75M in equity- up front- research milestones and is eligible to receive ~$1.3B as research- development- regulatory- and commercial milestones across up to five potential programs. Additionally- Obsidian will receive royalties on sales of products that emerge from the collaboration
• Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies to treat serious diseases. Vertex to get an exclusive option to license WW rights to candidates discovered and developed under the collaboration
• Upon option exercise- Vertex will be responsible for further pre/clinical development and commercialization of the therapies

  Ref: Business Wire | Image: Vertex